

NCCN Guidelines for Neuroendocrine and Adrenal Tumors V.1.2021 – Annual on 12/11/2020

Guideline Page and Request	Panel Discussion/References	Institution Vote			
		YES	NO	ABSTAIN	ABSENT
<p>NET-6 Internal request:</p> <p>Comment to consider removing the following adjuvant therapy option for locoregional thymus NET (stage IIIA/B) if low grade (typical carcinoid) following resection: Consider RT + cytotoxic chemotherapy.</p>	<p>Based on the discussion, the panel consensus supported the removal of the following adjuvant therapy option for locoregional thymus NET (stage IIIA/B) if low grade (typical carcinoid) following resection: Consider RT + cytotoxic chemotherapy.</p>	26	0	0	5
<p>PDNEC-1 Internal request:</p> <p>Comment to reassess the data for nivolumab + ipilimumab for metastatic poorly differentiated neuroendocrine carcinoma, and to remove the following language from the recommendation: “for non-pancreatic NET”.</p>	<p>Based on the discussion, the panel consensus supported the continued listing of nivolumab + ipilimumab as a category 2B option to consider after chemotherapy for metastatic, poorly differentiated neuroendocrine carcinoma, but removed the following language from the recommendation: “for non-pancreatic NET”.</p>	26	0	0	5
<p>NE-F 4 of 5 Internal request:</p> <p>Consider the inclusion of FOLFIRINOX as an option for poorly differentiated neuroendocrine carcinoma/large or small cell (extrapulmonary), locoregional unresectable/metastatic disease.</p>	<p>Based on the review of the data and discussion, the panel consensus was to include FOLFIRINOX as an option for poorly differentiated neuroendocrine carcinoma/large or small cell (extrapulmonary), locoregional unresectable/metastatic disease. This is a category 2A.</p> <p>References:</p> <ol style="list-style-type: none"> Zhu J, Strosberg JR, Dropkin E, Strickler JH. Treatment of High-Grade Metastatic Pancreatic Neuroendocrine Carcinoma with FOLFIRINOX. J Gastrointest Cancer. 2015;46(2):166-169. doi:10.1007/s12029-015-9689-0 Borghesani M, Reni A, Zaninotto E, et al. Outcomes of upfront treatment with mFOLFIRINOX regimen in G3 GEP-NENs: A monocentric retrospective experience. Paper presented at: 18th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease; February 25-27, 2021; Virtual Conference. 	26	0	0	5